Research ArticleClinical Review

A Comprehensive Guide to Long-Acting Injectable Antipsychotics for Primary Care Clinicians

Abirami Krishna, Shelby Goicochea, Rishubh Shah, Benton Stamper, Grant Harrell and Ana Turner
The Journal of the American Board of Family Medicine July 2024, 37 (4) 773-783; DOI: https://doi.org/10.3122/jabfm.2022.220425R2

References

  1. 1.↵
    1. Abed Faghri NM,
    2. Boisvert CM,
    3. Faghri S
    . Understanding the expanding role of primary care physicians (PCPs) to primary psychiatric care physicians (PPCPs): enhancing the assessment and treatment of psychiatric conditions. Ment Health Fam Med 2010;7:17–25.
    OpenUrlPubMed
  2. 2.
    1. Kim HO,
    2. Seo GH,
    3. Lee BC
    . Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry 2020;19:1.
    OpenUrlPubMed
  3. 3.↵
    1. Wei Y,
    2. Yan VKC,
    3. Kang W,
    4. et al
    . Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open 2022;5:e2224163.
    OpenUrlPubMed
  4. 4.↵
    1. Leucht C,
    2. Heres S,
    3. Kane JM,
    4. Kissling W,
    5. Davis JM,
    6. Leucht S
    . Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83–92.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Zhang L,
    2. Yu X,
    3. Fang YR,
    4. et al
    . Duration of untreated bipolar disorder: a multicenter study. Sci Rep 2017;7:44811.
    OpenUrlPubMed
  6. 6.
    1. Drancourt N,
    2. Etain B,
    3. Lajnef M,
    4. et al
    . Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand 2013;127:136–44.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.
    1. Altamura AC,
    2. Buoli M,
    3. Caldiroli A,
    4. et al
    . Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord 2015;182:70–5.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Medeiros GC,
    2. Senço SB,
    3. Lafer B,
    4. Almeida KM
    . Association between duration of untreated bipolar disorder and clinical outcome: data from a Brazilian sample. Braz J Psychiatry 2016;38:6–10.
    OpenUrlPubMed
  9. 9.↵
    1. Stilwell K,
    2. Pelkey L,
    3. Platt T,
    4. et al
    . Survey of primary care provider comfort in treating psychiatric patients in 2 community clinics: a pilot study. Prim Care Companion CNS Disord 2022;24.
  10. 10.↵
    1. Loeb DF,
    2. Bayliss EA,
    3. Binswanger IA,
    4. Candrian C,
    5. deGruy FV
    . Primary care physician perceptions on caring for complex patients with medical and mental illness. J Gen Intern Med 2012;27:945–52.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Alvarez-Jimenez M,
    2. Priede A,
    3. Hetrick SE,
    4. et al
    . Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012;139:116–28.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Chakrabarti S
    . Treatment-adherence in bipolar disorder: a patient-centred approach. World J Psychiatry 2016;6:399.
    OpenUrlPubMed
  13. 13.↵
    1. Emsley R,
    2. Chiliza B,
    3. Asmal L,
    4. Harvey BH
    . The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Jawad I,
    2. Watson S,
    3. Haddad PM,
    4. Talbot PS,
    5. McAllister-Williams RH
    . Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol 2018;8:349–63.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Lähteenvuo M,
    2. Tanskanen A,
    3. Taipale H,
    4. et al
    . Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 2018;75:347–55.
    OpenUrlPubMed
  16. 16.↵
    1. Calabrese JR,
    2. Sanchez R,
    3. Jin N,
    4. et al
    . Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017;78:324–31.
    OpenUrlPubMed
  17. 17.↵
    1. Quiroz JA,
    2. Yatham LN,
    3. Palumbo JM,
    4. Karcher K,
    5. Kushner S,
    6. Kusumakar V
    . Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156–62.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Vieta E,
    2. Montgomery S,
    3. Sulaiman AH,
    4. et al
    . A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22:825–35.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Yatham LN,
    2. Kennedy SH,
    3. Parikh SV,
    4. et al
    . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97–170.
    OpenUrlCrossRef
  20. 20.↵
    1. Ostuzzi G,
    2. Bertolini F,
    3. Del Giovane C,
    4. et al
    . Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry 2021;178:424–36.
    OpenUrlPubMed
  21. 21.↵
    1. Richelson E
    . Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60 Suppl 10:5–14.
    OpenUrl
  22. 22.↵
    1. Horacek J,
    2. Bubenikova-Valesova V,
    3. Kopecek M,
    4. et al
    . Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389–409.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Keepers GA,
    2. Fochtmann LJ,
    3. Anzia JM,
    4. et al
    . The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020;177:868–72.
    OpenUrlCrossRefPubMed
  24. 24.
    1. DeJongh BM
    . Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin 2021;11:311–9.
    OpenUrlPubMed
  25. 25.↵
    1. Factor SA,
    2. Burkhard PR,
    3. Caroff S,
    4. et al
    . Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol 2019;18:880–90.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Glocker C,
    2. Grohmann R,
    3. Burkhardt G,
    4. et al
    . Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm (Vienna) 2023;130:153–63.
    OpenUrlPubMed
  27. 27.
    1. Xiong GL,
    2. Pinkhasov A,
    3. Mangal JP,
    4. et al
    . QTc monitoring in adults with medical and psychiatric comorbidities: expert consensus from the Association of Medicine and Psychiatry. J Psychosom Res 2020;135:110138.
    OpenUrlPubMed
  28. 28.↵
    1. Sajatovic M,
    2. Ross R,
    3. Legacy SN,
    4. et al
    . Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat 2018;14:1475–1492.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Heres S,
    2. Kraemer S,
    3. Bergstrom RF,
    4. Detke HC
    . Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol 2014;29:299–312.
    OpenUrlCrossRefPubMed
  30. 30.↵
    Abilify Maintena (aripiprazole extended-release injectable suspension, for intramuscular use) Package Insert. Revised: July 2015. Otsuka America Pharmaceutical, Inc., Rockville, MD 20850. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf.
  31. 31.↵
    1. Uguz F
    . A new safety scoring system for the use of psychotropic drugs during lactation. Am J Ther 2021;28:e118–e126.
    OpenUrlPubMed
  32. 32.↵
    1. Uguz F
    . Second-generation antipsychotics during the lactation period. J Clin Psychopharmacol 2016;36:244–252.
    OpenUrlPubMed
  33. 33.↵
    Abilify Maintena prices, coupons & savings tips - goodrx. GoodRx, Inc. 2023. Accessed January 2, 2023. Available at: https://www.goodrx.com/invega-sustenna.
  34. 34.↵
    ARISTADA® (aripiprazole lauroxil extended-release injectable suspension, for intramuscular use) Package Insert. Otsuka America Pharmaceutical, Inc., Rockville, MD 20850. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf. Accessed 1/3/2023.
  35. 35.↵
    ARISTADA INITIO® (aripiprazole lauroxil extended-release injectable suspension, for intramuscular use) Package Insert. Otsuka America Pharmaceutical, Inc., Rockville, MD 20850. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209830lbl.pdf. Accessed 1/3/2023.
  36. 36.↵
    Abilify Aristada prices, coupons & savings tips - goodrx. GoodRx, Inc. 2023. Accessed January 2, 2023. Available at: https://www.goodrx.com/invega-sustenna.
  37. 37.↵
    Fluphenazine Decanoate Injection Package Insert. Bedford Laboratories; 2017.
  38. 38.↵
    1. Kreyenbuhl J,
    2. Buchanan RW,
    3. Dickerson FB,
    4. Dixon LB
    , Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36:94–103.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Poolsup N,
    2. Li Wan Po A,
    3. Knight TL
    . Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000;25:197–220.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Diav-Citrin O,
    2. Shechtman S,
    3. Ornoy S,
    4. et al
    . Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66:317–322.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Stahl SM
    . Stahl’s Essential Psychopharmacology. Cambridge University Press; 2022.
  42. 42.↵
    Fluphenazine Decanoate prices, Coupons & savings tips - goodrx. GoodRx, Inc. 2023. Accessed January 2, 2023. Available at: https://www.goodrx.com/invega-sustenna.
  43. 43.↵
    Fluphenazine. National Institute of Diabetes and Digestive and Kidney Diseases; 2018. Accessed June 6, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548610/.
  44. 44.↵
    1. Siragusa S,
    2. Bistas KG,
    3. Saadabadi A
    . Fluphenazine. StatPearls Publishing; 2023. Accessed June 6, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459194/.
  45. 45.↵
    1. Pacey AA,
    2. Povey AC,
    3. Clyma JA
    , Participating Centres of Chaps-UKet al. Modifiable and non-modifiable risk factors for poor sperm morphology. Hum Reprod. 2014;29:1629–1636.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Center for Drug Evaluation and Research. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. U.S. Food and Drug Administration. August 4, 2017. Accessed June 6, 2023. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-antipsychotic-drug-labels-updated-use-during-pregnancy-and-risk.
  47. 47.↵
    1. Iqbal MM,
    2. Aneja A,
    3. Rahman A,
    4. et al
    . The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation. Psychiatry (Edgmont) 2005;2:36–44.
    OpenUrlPubMed
  48. 48.↵
    1. Galbally M,
    2. Snellen M,
    3. Power J
    . Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf 2014;5:100–109.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Oyebode F,
    2. Rastogi A,
    3. Berrisford G,
    4. Coccia F
    . Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012;135:71–77.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. McElhatton PR
    . The use of phenothiazines during pregnancy and lactation [published correction appears in Reprod Toxicol 1993;7(2):187]. Reprod Toxicol 1992;6:475–490.
    OpenUrlPubMed
  51. 51.
    American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–789.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Haloperidol tablets package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2020 Jul.
  53. 53.↵
    Haldol Decanoate (haloperidol decanoate) for intramuscular injection package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2020 Nov.
  54. 54.↵
    Haloperidol decanoate prices, coupons & savings tips - goodrx. GoodRx, Inc. 2023. Accessed January 2, 2023. Available at: https://www.goodrx.com/invega-sustenna.
  55. 55.↵
    1. Jann MW,
    2. Saklad SR,
    3. Ereshefsky L,
    4. Richards AL,
    5. Harrington CA,
    6. Davis CM
    . Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1986;90:468–470.
    OpenUrlPubMed
  56. 56.↵
    1. Desai HD,
    2. Seabolt J,
    3. Jann MW
    . Smoking in patients receiving psychotropic medications. CNS Drugs 2001;15:469–494.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Reis M,
    2. Källén B
    . Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279–288.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    Food and Drug Administration Medwatch. Antipsychotic drugs: Class labeling change - Treatment during pregnancy and potential risk to newborns. Retrieved February 22, 2001. Available at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm.
  59. 59.↵
    Massachusetts General Hospital Center for Women’s Mental Health. National Pregnancy Registry for Psychiatric Medications. Available at: https://womensmentalhealth.org/research/pregnancyregistry/.
  60. 60.↵
    Invega Sustenna (paliperidone palmitate). U.S. Food and Drug Administration. June 2017. Accessed January 2, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022264s023lbl.pdf.
  61. 61.↵
    Invega Sustenna prices, Coupons & savings tips - goodrx. GoodRx, Inc. 2023. Accessed January 2, 2023. Available at: https://www.goodrx.com/invega-sustenna.
  62. 62.↵
    1. Bossie CA,
    2. Sliwa JK,
    3. Ma YW,
    4. Fu DJ,
    5. Alphs L
    . Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 2011;11:79.
    OpenUrlPubMed
  63. 63.↵
    Use of Invega, Invega Sustenna, Invega trinza, and Invega Hafyera in pregnancy or lactation. Accessed January 2, 2023. Available at: https://www.janssenscience.com/products/invega-sustenna/medical-content/use-of-invega-invega-sustenna-invega-trinza-and-invega-hafyera-in-pregnancy-or-lactation.
  64. 64.↵
    Invega Trinza (paliperidone palmitate). U.S. Food and Drug Administration. August 2021. Accessed January 3, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946Orig1s011lbl.pdf.
  65. 65.↵
    Invega Hafyera (paliperidone palmitate). U.S. Food and Drug Administration. August 2021. Accessed July 1, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946s010lbl.pdf.
  66. 66.↵
    Risperdal Consta. U.S. Food and Drug Administration. February 2021. Accessed January 3, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020272Orig1s083,020588Orig1s071,021444Orig1s057,021346Orig1s061lbl.pdf.
  67. 67.↵
    Rykindo. U.S. Food and Drug Administration. January 2023. Accessed February 20, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212849s000lbl.pdf.
  68. 68.↵
    Perseris. U.S. Food and Drug Administration. July 2017. Accessed February 20, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210655s000lbl.pdf.
  69. 69.↵
    Uzedy. U.S. Food and Drug Administration. April 2023. Accessed February 20, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213586s000lbl.pdf.
  70. 70.↵
    1. Riboldi I,
    2. Cavaleri D,
    3. Capogrosso CA,
    4. Crocamo C,
    5. Bartoli F,
    6. Carrà G
    . Practical guidance for the use of long-acting injectable antipsychotics in the treatment of schizophrenia. Psychol Res Behav Manag 2022;15:3915–3929.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords